These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 23931455)

  • 1. Toxicokinetic and mechanistic basis for the safety and tolerability of liposomal amphotericin B.
    Loo AS; Muhsin SA; Walsh TJ
    Expert Opin Drug Saf; 2013 Nov; 12(6):881-95. PubMed ID: 23931455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amphotericin B formulations: a comparative review of efficacy and toxicity.
    Hamill RJ
    Drugs; 2013 Jun; 73(9):919-34. PubMed ID: 23729001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice.
    Rust DM; Jameson G
    Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
    Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposomal amphotericin B: clinical experience and perspectives.
    Gibbs WJ; Drew RH; Perfect JR
    Expert Rev Anti Infect Ther; 2005 Apr; 3(2):167-81. PubMed ID: 15918775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of liposomal amphotericin B formulation.
    Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
    J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AmBisome: relationship between the pharmacokinetic characteristics acquired by liposomal formulation and safety/efficacy.
    Takemoto K; Kanazawa K
    J Liposome Res; 2017 Sep; 27(3):186-194. PubMed ID: 27328721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics characterization of liposomal amphotericin B: investigation of clearance process and drug interaction potential.
    Matsui S; Imai S; Yabuki M; Komuro S
    Arzneimittelforschung; 2009; 59(9):461-70. PubMed ID: 19856794
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study.
    Falci DR; da Rosa FB; Pasqualotto AC
    Mycoses; 2015 Feb; 58(2):104-12. PubMed ID: 25590436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model.
    Khan MA; Owais M
    J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the safety and efficacy of liposomal amphotericin B (L-AMB) in children.
    Sunakawa K; Tsukimoto I; Tsunematsu Y; Honda M; Iwai N; Maniwa T; Haigo H; Suzuki K; Mori T
    J Infect Chemother; 2012 Aug; 18(4):456-65. PubMed ID: 22286407
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment.
    Alvarez-Lerma F; Soriano MC; Rodríguez M; Catalán M; Llorente AM; Vidart N; Garitacelaya M; Maraví E; Fernández E; Alvarado F; López M; Alvarez-Sánchez B; Espinosa J; Quintana E;
    Rev Esp Quimioter; 2012 Sep; 25(3):206-15. PubMed ID: 22987267
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liposomal and lipid-based formulations of amphotericin B.
    de Marie S
    Leukemia; 1996 Jun; 10 Suppl 2():s93-6. PubMed ID: 8649062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model.
    Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
    Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
    Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis.
    Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Liposomal amphotericin B: a unique pharmacokinetic profile. An unfinished story].
    Azanza Perea JR; Barberán J
    Rev Esp Quimioter; 2012 Mar; 25(1):17-24. PubMed ID: 22488537
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma protein binding of amphotericin B and pharmacokinetics of bound versus unbound amphotericin B after administration of intravenous liposomal amphotericin B (AmBisome) and amphotericin B deoxycholate.
    Bekersky I; Fielding RM; Dressler DE; Lee JW; Buell DN; Walsh TJ
    Antimicrob Agents Chemother; 2002 Mar; 46(3):834-40. PubMed ID: 11850269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of aerosolized liposomal versus deoxycholate amphotericin B formulations for prevention of invasive fungal infections following lung transplantation: a retrospective study.
    Lowry CM; Marty FM; Vargas SO; Lee JT; Fiumara K; Deykin A; Baden LR
    Transpl Infect Dis; 2007 Jun; 9(2):121-5. PubMed ID: 17461997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.